| | | Combination indexa |
|---|
Cell line | α-TEA:drugb | ED50 | ED75 | ED90 | Mean ± SDc | |
|---|
DOXO | | | | | | |
MDA-MB-231 | 20:1 | 0.48 | 0.40 | 0.35 | 0.41 ± 0.07 | Synergismd |
BT-20 | 20:1 | 0.48 | 0.52 | 0.58 | 0.53 ± 0.05 | Synergism |
CDDP | | | | | | |
MDA-MB-231 | 2:1 | 0.55 | 0.44 | 0.36 | 0.45 ± 0.10 | Synergism |
BT-20 | 4:1 | 0.68 | 0.74 | 0.84 | 0.75 ± 0.08 | Synergism |
- MDA-MB-231 and BT-20 breast cancer cells were treated with different concentrations of α-TEA, doxorubicin (DOXO), and cisplatin (CDDP) alone and in combination for 24 hours. Apoptosis was determined using annexin V-FITC/PI staining/fluorescence-activated cell sorter assay as described in Material and methods. aFor each combination treatment, a combination index was calculated using commercially available software (Calcusyn; Biosoft, Manchester, UK). bThe ratio for the concentrations used in combination treatments was determined from the data in Figure 1. cThe mean ± standard deviation (SD) calculated from the combination index values of the effective dose in 50% (ED50), the effective dose in 75% (ED75) and the effective dose in 90% (ED90) of the population. dCombination index value: <1.0, synergism; 1.0, additive effect; >1.0, antagonism.
